-- 4DMedical（澳交所代碼：4DX）週四向澳洲證券交易所提交的文件顯示，截至目前，2026財年營業收入為500萬澳元，較上年同期增長12%，毛利率超過90%。 該公司在另一份文件中揭露，去年同期營業收入為450萬澳元。 截至3月份的第三財季，客戶營收年增18%，從120萬澳元增至140萬澳元。 截至3月份的九個月，基礎軟體即服務（SaaS）營收年增24%，主要得益於企業對企業（B2B）SaaS網站和經銷商通路滲透率的提高。
Related Articles
International
Saudi Arabia's Quarterly GDP Down 1.5% in Q1, Flash Data Shows
Saudi Arabia's seasonally adjusted real gross domestic product decreased 1.5% on a quarterly basis in the first quarter, compared with a 1.4% rise in the prior three-month period, flash data from the General Authority for Statistics showed Thursday.Annually, the Saudi Arabian economy grew 2.8% during the three-month period, after a 5% increase in the previous quarter.
$^TASI
Asia
Diagens Biotechnology's 2025 Loss Widens
Hangzhou Diagens Biotechnology (HKG:2526) booked 67.1 million yuan in attributable loss for 2025, widening from a loss of 43.4 million yuan a year earlier, according to a Hong Kong bourse filing Wednesday.The medical imaging products maker's shares gained nearly 3% in afternoon trade Thursday.Loss per share was 0.84 yuan, compared with 0.55 yuan in 2024.Revenue more than doubled year on year to 164.4 million yuan from 70.4 million yuan.
$HKG:2526
Asia
Daqin Railway Q1 Profit Down 7%; Shares Slip 3%
Daqin Railway Co (SHA:601006) posted first-quarter attributable net profit of 2.38 billion yuan, down 6.9% from 2.56 billion yuan the previous year.Earnings per share slid to 0.12 yuan from 0.13 yuan, according to a Thursday filing with the Shanghai bourse.Operating revenue climbed 4.3% year over year to 18.6 billion yuan from 17.8 billion yuan.Shares of the railway operator declined 3% in recent trade.
$SHA:601006